Pfizer Adds Kosan GI Program To Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies will initiate Phase I study for Kosan’s lead motilin agonist compound in early 2007.
You may also be interested in...
Roche Backs Out Of Kosan Epothilone Deal
Kosan is “actively seeking” a new partner to begin Phase II trial for KOS-1584 after Roche unexpectedly terminates five-year collaboration.
Roche Backs Out Of Kosan Epothilone Deal
Kosan is “actively seeking” a new partner to begin Phase II trial for KOS-1584 after Roche unexpectedly terminates five-year collaboration.
Pfizer Terminates Torcetrapib Program
Company will investigate whether an increased risk of mortality is a class effect of CETP inhibitors.